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PAF elicits a rapid, concentration-dependent elevation of platelet cytosolic free calcium ([Car]), measured 
by quin2. Elevation of [Car] is transient, and the rate of reversal increases with agonist concentration. Aden- 
ylate cyclase stimulants (PGI,, PGDJ and 8-bromo CAMP; a guanylate cyclase stimulant (sodium nitro- 
prusside) and 8-bromo cGMP; and a protein kinase C stimulant (phorbol myristate acetate) block the eleva- 
tion of [Car] induced by PAF, and accelerate its reversal. These results suggest hat CAMP, cGMP and 1,2- 
diacylglycerol (DAG) could act as second messengers to regulate [Car] in platelets. As PAF is known to 
stimulate platelet phosphoinositide hydrolysis (ergo DAG formation) but fails to elevate platelet CAMP or 
cGMP. it is proposed that DAG, via activation of protein kinase C, may act as an endogenous modulator 
of platelet [Car]: an action that contributes to the role of DAG as a bi-directional regulator of platelet reac- 
tivity. 
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1. INTRODUCTION 
Platelet activation is mediated by the synergistic 
interaction of Ca2+-dependent and Ca2+-indepen- 
dent ‘pathways’. The former requires that the 
platelet stimulatory agonists elicit an elevation of 
the cytosolic free Ca2+ concentration, [Car], and 
the latter that stimulatory agonists evoke forma- 
tion of 1,2-diacylglycerol (DAG), the endogenous 
activator of protein kinase C [ 11. Elevation of [Car] 
and DAG formation result from a common recep- 
tor-activated transduction process: hydrolysis of 
inositol phospholipids - phosphatidylinositol 
(PtdIns), PtdIns 4-phosphate (PtdIns 4P) or more 
likely, PtdIns 4,5-bisphosphate (PtdIns 4,5P2) [2]. 
The phospholipase C-catalysed hydrolysis of 
PtdIns 4,5Pz yields DAG and inositol 1,4,5-tris- 
phosphate (Ins P3) which can mobilise Ca2+ from 
intracellular storage sites [3]. 
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As in other cell types, there must exist within 
platelets homeostatic mechanisms for maintaining 
resting [Car] at or near 100 nM, some lOOOO-fold 
less than the free Ca2+ concentration in plasma. 
Moreover, platelet activation may be a reversible 
process [4], and the elevation of [Car] (and, in- 
cidentally, of DAG or phosphatidic acid) observed 
following the addition of thrombin, PAF, 
TxAz-mimetics, ADP, vasopressin and 5HT to 
human platelets are not maintained [5]. Thus, 
besides the homeostatic processes that maintain 
resting [Car] at or near 100 nM, there must exist 
within platelets mechanisms for restoring elevated 
[Car] towards basal. In other cells, [Car] is 
regulated by systems that limit Ca2+ influx, 
enhance Ca2+ sequestration and promote Ca2+ ex- 
trusion [6]. Similar mechanisms may operate in 
platelets. Mitochondria and the dense tubular 
system have been implicated as Ca*+-sequestering 
organelles, with the latter being of major impor- 
tance. The isolated dense tubular system actively 
accumulates Ca2+ and contains a (Ca’+ + Mg’+)- 
ATPase [7]. Sequestration of Ca2+ within this 
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organelle is augmented by CAMP [8] and inhibited 
by phenothiazines [9], putative calmodulin ‘an- 
tagonists’ which exert numerous effects including 
inhibition of protein kinase C [lo]. The 
mechanisms underlying extrusion of platelet Ca2+ 
are less well characterised. In other tissues Ca2+ ef- 
flux is commonly mediated via (Ca’+ +Mg’+)- 
ATPase and/or Na+/Ca2+ exchange [6]. How- 
ever the presence of a plasma membrane 
(Ca2’ +Mg2+)-ATPase in platelets remains to be 
demonstrated, and Na+/Ca2+ exchange does not 
operate in resting platelets [l 11, although it may 
well operate at elevated [Caf]. 
Adenylate cyclase stimulants inhibit platelet 
reactivity and suppress agonist-induced elevation 
of [Car] [12]. This is taken as evidence that CAMP 
can regulate platelet Ca2+ homeostasis. However, 
other endogenous modulators of Ca2+ homeostasis 
may exist. Agents that stimulate cGMP formation 
inhibit platelet reactivity, but the mechanism(s) 
underlying this effect are poorly understood [13]. 
Tumour-promoting phorbol esters (e.g., phorbol 
12-myristate 13-acetate, PMA), which mimic the 
effects of endogenous DAG in the activation of 
protein kinase C, inhibit agonist-induced elevation 
of [Car] in platelets and other cells [14,15]. Here, 
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Fig.1. PAF-induced elevation of platelet [Car]. QuinZlabelled human platelets were stimulated with PAF at the 
concentrations indicated. Changes in [Car] were calculated from the observed changes in dye fluorescence. (A) 
Concentration-response relationship: results, expressed as increase in [Car] above basal (90 nM) are mean values f SD 
of 6-9 observations using platelets from different donors. (B) Fluorescence records: the data shown are typical of 4 
experiments using platelets from different donors. 
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using adenylate cyclase stimulants (PGIt, PGD2) 
and 8-bromo CAMP, a guanylate cyclase stimulant 
(sodium nitroprusside, NaNP) and 8-bromo 
cGMP, and a protein kinase C stimulant (PMA), 
we investigated the possible role(s) of CAMP- 
mediated, cCMP-mediated and protein kinase C- 
mediated processes in regulating resting [Caf] and 
PAF-induced elevation of [Car] in human platelets. 
3. RESULTS 
2. EXPERIMENTAL 
Platelet cytosohc free Cat+ was monitored by 
using the fluorescent quinoline dye, quin2, essen- 
tially as in [ 161. 
CAMP and cGMP were extracted from platelets 
using ethanol. Extracts were evaporated to 
dryness, reconstituted in Na-acetate buffer 
(50 mM, pH 6.2) and acetylated using acetic 
anhydride :triethylamine (1: 2, v/v). Authentic 
standards were similarly treated, and the CAMP 
and cGMP contents of platelet extracts were 
estimated by radioimmunoassay using iodinated 
tracers [ 171. 
Resting [Caf] in human platelets was 90 + 3 nM 
(mean + SE, n = 46). PAF induced a rapid, 
concentration-dependent elevation of [Car] to a 
maximum of around 400-700 nM in different ex- 
periments. The concentration-response relation- 
ship is depicted in fig.lA and typical fluorescence 
records from a single experiment are shown in 
fig.lB. Note that as the concentration of agonist 
increases, the rate and extent of the resultant 
changes in fluorescence ([Car]) also increase until a 
maximum value is attained. Thereafter the 
fluorescence (and [Cad) declines towards the 
resting value. The rate of decline of fluorescence 
(and [Cad) varies with the concentration of 
agonist: the response elicited by a high concentra- 
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mmol) and guanosine 3 ’ ,5 ’ -cyclic phosphoric acid 
2’ -O-succinyl-3-[1251]iodotyrosine methyl ester 
(600 Ci/mmol) were obtained from Amersham In- 
ternational, Amersham, England. PGI2, PGD2, 
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described [14,16]. Other reagents were dissolved in 
iso-osmotic sahne. 
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Fig.2. Inhibition of PAP-induced elevation of [Car]. 
QuinZlabelled human platelets were pre-incubated with 
PGIz, PGD2, NaNP, PMA, 8-bromo CAMP, I-bromo 
cGMP or appropriate vehicle, before the addition of a 
sub-maximal concentration of PAF (10-100 nM). 
Results (mean & SD, n = 3-9) are expressed as percent 
Fig.3. Effects of PGI2, PGDz and NaNP on platelet 
CAMP and cGMP. Platelets preincubated (5 min, 
37°C) with the phosphodiesterase inhibitor, 
isobutylmethylxanthine (100 FM), were then incubated 
(2 min, 37T) with PC&, PGD2 or NaNP at the 
concentrations indicated. PIatelet cAMP and cGMP 
were measured by radioimmunoassay. Results are mean 
values + SE, n = 4-8. (0, control; l , PGI2; A , PGD*; 
inhibition of the control (vehicle + PAF) response. 0, NaNP). 
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tion of agonist decays more rapidly than the 
response elicited by a lower concentration of 
agonist. Addition of EGTA (to chelate ex- 
tracellular Ca*+, and thus abolish Ca*+ influx), at 
the peak of the PAF response, did not affect the 
rate of decline of fluorescence (not shown). 
Addition of PGI2 (< 1 PM), PGD;! (< 1 yM), 
NaNP (< 10 PM) or PMA (< 1 FM) to platelets did 
not alter the basal [Car]. However the elevation of 
[Car] induced by a sub-maximal concentration of 
PAF (lo-100 nM), was inhibited in platelets pre- 
treated with PGI2, PGD2, NaNP or PMA (2 min, 
37°C) and with 8-bromo CAMP or 8-bromo cGMP 
(5 min, 37°C) (fig.2). When tested over the active 
concentration range, PGI2 and PGD2 elicit a 
marked elevation of platelet CAMP and a small 
elevation of platelet cGMP:NaNP induced a 
marked elevation of platelet cGMP but did not 
elevate platelet CAMP (fig.3). 
The possible role of endogenous CAMP, cGMP 
and DAG in mediating the reversal of the PAF- 
induced elevation of [Car] was investigated: (i) by 
adding PGI2, NaNP and PMA at the peak of the 
fluorescence signal and monitoring the rate of 
decay of the fluorescence; and (ii) by measuring 
changes in platelet CAMP and cGMP with time 
following PAF addition to platelets. Fig.4 in- 
dicates that all 3 agents accelerated the decline in 
fluorescence (and of [Car]). No changes in the 
basal levels of platelet CAMP (12 f 1 pmol/lO* 
cells, mean +_ SE, n = 8) or platelet cGMP (315 + 
30 fmol/lO’ cells, mean +- SE, n = 8) were ob- 
served for up to 5 min following the addition of 
PAF (< 100 nM) to platelets. 
4. DISCUSSION 
PAF elicits a rapid, concentration-dependent 
elevation of [Car] in human platelets. This eleva- 
tion of [Car], derived predominantly (>80%) via 
influx of intracellular Ca*+ [5], is reversible, and 
the rate of decline varies with the agonist concen- 
tration. That this decline occurs even in the con- 
tinued presence of the agonist suggests that the 
receptors undergo rapid desensitisation and that 
normal homeostatic mechanisms restore [Cad 
towards basal values. As the rate of decline of 
fluorescence (i.e. [Car]) is unaltered by addition of 
EGTA at the peak of the quin2 signal, it is 
probable that the decline in [Cad reflects seques- 
tration and/or extrusion of Ca*+ rather than in- 
hibition of persisting Ca*+ influx and/or mobilisa- 
tion of internal Ca*+. 
8-Bromo CAMP and agents that stimulate 
adenylate cyclase; 8-bromo cGMP and agents that 
stimulate guanylate cyclase, and tumour- 
promoting phorbol esters, all result in inhibition of 
the elevation of [Car] induced by PAF. Such an ac- 
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Fig.4. Reversal of PAF-induced elevation of [Cad. PC&, NaNP and PMA at the concentrations indicated, or 
appropriate vehicle, were added to quin2-labelled human platelets at the peak of the fluorescence change elicited by 
PAF. Changes in [Cad were calculated from the observed changes in dye fluorescence. The data shown are typical of 
at least 4 experiments using platelets from different donors. 
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tion on [Car] may contribute to the inhibitory ef- 
fects that CAMP, cGMP [13] and protein kinase C 
[18] exert on agonist-induced platelet activation. 
Suppression of agonist-induced elevation of [Car] 
may result from effects on processes that promote 
Ca2+ influx and/or mobilisation of internal Ca2+, 
or on processes that promote Ca2+ sequestration 
and/or extrusion. PAF is a potent stimulus of 
human platelet phosphoinositide metabolism [6] 
(one of) the molecular mechanism(s) that mediates 
elevation of [Cad in platelets, as in other cells [2]. 
Consequently, CAMP-mediated, cGMP-mediated 
and PMA-mediated inhibition of PAF-induced 
Ca2+ flux may reflect inhibition of phospholipase 
C. In support of this, there is evidence that CAMP, 
cGMP and PMA can inhibit phosphoinositide 
metabolism in platelets [14,19,20]. Moreover when 
added at the peak of the elevation in [Cad elicited 
by PAF, PGIz, NaNP and PMA, all accelerate the 
decline in fluorescence, and hence in [Cad. The ac- 
celerated decline in the PAF-induced Ca2+ signal 
suggests that PG12, NaNP and PMA also affect 
processes involved in Ca2+ sequestration or extru- 
sion. The mechanism(s) underlying Ca2+ efflux 
from platelets are ill understood, but apparently 
do not involve plasma membrane Ca2+/Mg2+- 
ATPase or Na+/Ca’+ exchange [ 111, although 
there is evidence for the involvement of the plasma 
membrane glycoprotein IIb/IIIa complex [21]. 
Consequently, how, and if, Ca2+ efflux from 
platelets can be modulated by processes regulated 
by CAMP, cGMP or DAG remains an enigma. The 
major intracellular organelle implicated in Ca2+ 
sequestration is the dense tubular system, and 
CAMP is known to promote accumulation of Ca2+ 
by this organelle [8]. The qualitatively similar ef- 
fects elicited by NaNP and PMA would suggest 
that cGMP and DAG also promote Ca2+ se- 
questration in the dense tubular system. The role 
of cGMP in Ca2+ sequestration within platelets has 
not been examined. In other systems, e.g. vascular 
smooth muscle, although reported to promote 
Ca2+ sequestration within a microsomal fraction 
[22], the effects of cGMP on Ca2+ homeostasis are 
controversial [23]. Although phenothiazines in- 
hibit Ca2+ uptake by the dense tubular system, 
such effects could not be attributed to an interac- 
tion with calmodulin [9]. However, phenothiazines 
are known to inhibit protein kinase C in platelets 
[lo]. Such a role for protein kinase C in Ca2+ se- 
questration would be consistent with the effects of 
PMA observed in the present study using platelets, 
and in other tissues [24]. 
As platelet stimulatory agonists do not elicit 
CAMP formation, it is unlikely that, unless ex- 
posed to an adenylate cyclase stimulant, endog- 
enous CAMP would subserve a physiological role 
in modulating [Car] in platelets. Certain platelet 
stimulatory agonists have been reported to cause 
cGMP formation [13]: this occurs relatively late 
after addition of agonist and thus could be of im- 
portance in limiting or terminating platelet respon- 
siveness. Our failure to detect cGMP formation in 
response to PAF may indicate some agonist spe- 
cificity in platelet cGMP formation, or may reflect 
that aggregation (which did not occur under our 
experimental conditions) is a prerequisite for 
cGMP formation [13]. Irrespective of their 
physiological importance, CAMP or cGMP may be 
of pharmacological or therapeutic importance as 
endogenous regulators of [Car] in platelets. In con- 
trast, phosphoinositide hydrolysis, DAG forma- 
tion and activation of protein kinase C are also se- 
quelae of receptor occupancy that accompany 
agonist-induced elevation of [Car]. Thus DAG, via 
activation of protein kinase C, may serve as an en- 
dogenous negative feedback regulator of elevated 
platelet [Car]. In view of the role of DAG in 
mediating the so-called ‘calcium-independent’ 
pathway of platelet activation, this would indicate 
that DAG can function as a bi-directional 
regulator of platelet reactivity. Indeed, evidence 
for such a function is now emerging in numerous 
cell types [15,25]. 
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